Role of Proteasomes in T Cell Activation and Proliferation
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The role of proteasomes in T cell activation, proliferation, and apoptosis was investigated using a proteasome-specific inhibitor lactacystin (LAC). Inhibition of the proteasome activity by LAC repressed the mitogen-induced T cell proliferation. The proteasome activity was definitively required for the T cells to progress from the G0 to S phase. It was necessary to optimize the progress from the G1/S boundary to the G2/M phase, but not for the progress from the G2/M phase to the next G1 phase. Probably as a result of a blockage of cell cycle progress, the cycling, but not the resting, T cells underwent apoptosis when treated with LAC. Mechanistically, we have found that cyclin-dependent kinase-2 (CDK2) and the cyclin E-associated kinase (largely CDK2), but not CDK4, in the G1 phase were strongly inhibited by LAC. This could be an important mechanism for the proteasome to regulate the cell cycle. The degradation of cyclin E in the late G1 and early S phases was dependent on the proteasome, although it was unlikely that this accounted for the observed inhibition of T cell proliferation. There was a reduced decay of p27Kip1 in the late G1 phase when the proteasome activity was suppressed, and this might be a contributing mechanism for the observed inhibition of CDK2 activity. Interestingly, p21Cip1 was up-regulated during the G1 phase, and the up-regulation was inhibited by LAC. Our study shows that the proteasome plays pivotal roles in regulating T cell activation and proliferation, and its effect is probably exerted through multiple mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583 · cited 2×
“It has been reported that LAC irreversibly inhibits the chymotrypsin-like and trypsin-like activities of the proteasome when tested in vitro using the purified 20S complex (25).”
BackgroundNew functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
Luo, Y., Hurwitz, J., & Massagué, J. (1995) · Nature · doi:10.1038/375159a0 · Cited by 549 · cited 3×
“Indeed, p21 Cip1 protein has a domain that binds to the proliferation cell nuclear Ag, and a different domain that binds to the cyclin E-CDK2 (60).”
Background
Cited by
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190af83 · Cited by 392
The role of the ubiquitin-proteasome pathway in apoptosis
Orlowski, R. Z. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400505 · Cited by 386
A Giant Protease with Potential to Substitute for Some Functions of the Proteasome
Geier, E., Pfeifer, G., Wilm, M., Lucchiari-Hartz, M., Baumeister, W., Eichmann, K., & Niedermann, G. (1999) · Science · doi:10.1126/science.283.5404.978 · Cited by 375
Metadata
- Authors
- Wang, X., Luo, H., Chen, H., Duguid, W., & Wu, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 160
- Issue
- 2
- Pages
- 788-801
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2112193890
- Cited by
- 94
- References
- 6
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.